JP2018536697A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018536697A5 JP2018536697A5 JP2018534025A JP2018534025A JP2018536697A5 JP 2018536697 A5 JP2018536697 A5 JP 2018536697A5 JP 2018534025 A JP2018534025 A JP 2018534025A JP 2018534025 A JP2018534025 A JP 2018534025A JP 2018536697 A5 JP2018536697 A5 JP 2018536697A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- composition according
- protein
- homeoprotein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 10
- 231100000277 DNA damage Toxicity 0.000 claims 6
- 102000009331 Homeodomain Proteins Human genes 0.000 claims 6
- 108010048671 Homeodomain Proteins Proteins 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 108090000623 proteins and genes Proteins 0.000 claims 5
- 102000004169 proteins and genes Human genes 0.000 claims 5
- 206010053643 Neurodegenerative disease Diseases 0.000 claims 4
- 206010002026 Amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 201000001971 Huntington's disease Diseases 0.000 claims 3
- 101700054217 GBX2 Proteins 0.000 claims 2
- 101700046734 LHX9 Proteins 0.000 claims 2
- 206010061536 Parkinson's disease Diseases 0.000 claims 2
- 206010001897 Alzheimer's disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
Claims (10)
- ホメオタンパク質またはそのペプチド誘導体を含む、神経変性障害の処置および／または予防に使用される医薬組成物。
- 前記ホメオタンパク質が、Ｅｎｇｒａｉｌｅｄタンパク質、Ｇｂｘ２およびＬｈｘ９からなる群から選択される、請求項１に記載の医薬組成物。
- 前記神経変性疾患が、パーキンソン病、アルツハイマー病、筋萎縮性側索硬化症、ハンチントン病、筋萎縮性側索硬化症、および眼または耳に影響を及ぼす変性疾患からなる群から選択される、請求項１または２に記載の医薬組成物。
- 前記神経変性障害がパーキンソン病である、請求項３に記載の医薬組成物。
- 前記ホメオタンパク質がＥｎｇｒａｉｌｅｄタンパク質である、請求項１〜４のいずれか一項に記載の医薬組成物。
- 前記Ｅｎｇｒａｉｌｅｄタンパク質が、ＳＮｐｃ領域中に直接投与される、請求項５に記載の医薬組成物。
- 前記ホメオタンパク質またはそのペプチド誘導体が、一度で投与される、請求項１〜５のいずれか一項に記載の医薬組成物。
- 前記ホメオタンパク質が、Ｅｎｇｒａｉｌｅｄタンパク質であり、前記ＤＮＡ損傷関連疾患または前記ＤＮＡ損傷関連障害が、筋萎縮性側索硬化症である、請求項１または２に記載の医薬組成物。
- 前記ホメオタンパク質が、Ｇｂｘ２タンパク質であり、前記ＤＮＡ損傷関連疾患または前記ＤＮＡ損傷関連障害が、ハンチントン病である、請求項１または２に記載の医薬組成物。
- 前記ホメオタンパク質が、Ｌｈｘ９タンパク質であり、前記ＤＮＡ損傷関連疾患または前記ＤＮＡ損傷関連障害が、ハンチントン病である、請求項１または２に記載の医薬組成物。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306482 | 2015-09-23 | ||
| EP15306482.9 | 2015-09-23 | ||
| PCT/EP2016/072675 WO2017071889A1 (en) | 2015-09-23 | 2016-09-23 | Homeoproteins for use in the treatment of neurodegenerative disorders |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018536697A JP2018536697A (ja) | 2018-12-13 |
| JP2018536697A5 true JP2018536697A5 (ja) | 2019-09-05 |
| JP6860575B2 JP6860575B2 (ja) | 2021-04-14 |
Family
ID=54207439
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018534025A Active JP6860575B2 (ja) | 2015-09-23 | 2016-09-23 | 神経変性障害の処置に用いられるホメオタンパク質 |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US20190247461A1 (ja) |
| EP (2) | EP3352777B1 (ja) |
| JP (1) | JP6860575B2 (ja) |
| CN (1) | CN108289929A (ja) |
| CA (1) | CA2999209A1 (ja) |
| ES (1) | ES2895154T3 (ja) |
| PL (1) | PL3352777T3 (ja) |
| WO (1) | WO2017071889A1 (ja) |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2662698A1 (fr) * | 1990-06-05 | 1991-12-06 | Centre Nat Rech Scient | Nouveaux facteurs de croissance neurotropes comprenant un peptide homeoboite. |
| FR2855178B1 (fr) * | 2003-05-20 | 2005-08-05 | Centre Nat Rech Scient | Peptides modulateurs de l'activite du facteur de transcription engrailed |
| FR2897780B1 (fr) | 2006-02-28 | 2008-05-23 | Centre Nat Rech Scient | Utilisation de la proteine a homeodomaine engrailed comme anxiolytique |
| GB0625321D0 (en) * | 2006-12-19 | 2007-01-24 | Univ Surrey | Cancer biomarker |
| FR2926023B1 (fr) | 2008-01-09 | 2010-02-26 | Centre Nat Rech Scient | Utilisation d'une homoproteine de la famille bicoid pour le traitement du glaucome. |
| CN102549433A (zh) * | 2009-07-13 | 2012-07-04 | 萨里大学 | 治疗肽、多肽和核酸序列 |
| US9950033B2 (en) | 2012-02-29 | 2018-04-24 | Centre National De La Recherche Scientifique | Use of engrailed proteins for increasing dopamine synthesis by dopaminergic neurons |
-
2016
- 2016-09-23 CN CN201680059070.1A patent/CN108289929A/zh active Pending
- 2016-09-23 CA CA2999209A patent/CA2999209A1/en active Pending
- 2016-09-23 EP EP16777596.4A patent/EP3352777B1/en active Active
- 2016-09-23 WO PCT/EP2016/072675 patent/WO2017071889A1/en active Application Filing
- 2016-09-23 EP EP21189549.5A patent/EP3960195A1/en active Pending
- 2016-09-23 US US15/761,702 patent/US20190247461A1/en not_active Abandoned
- 2016-09-23 JP JP2018534025A patent/JP6860575B2/ja active Active
- 2016-09-23 ES ES16777596T patent/ES2895154T3/es active Active
- 2016-09-23 PL PL16777596T patent/PL3352777T3/pl unknown
-
2021
- 2021-06-16 US US17/349,746 patent/US20210379144A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3555629A4 (en) | USE OF APOE4 PATTERNED MEDIATION GENES FOR THE DIAGNOSIS AND TREATMENT OF ALZHEIMER'S DISEASE | |
| WO2017070647A8 (en) | Nicotinamide for use in the treatment and prevention of ocular neurodegenerative disorder (e.g. glaucoma) | |
| WO2012080729A3 (en) | Casein kinase 1delta (ck1delta) inhibitors and their use in the treatment of neurodegenerative diseases such as tauopathies | |
| JP2019524822A5 (ja) | ||
| WO2018060732A3 (en) | Compositions and methods for treating seizure disorders | |
| JP2016535786A5 (ja) | ||
| HRP20191055T1 (hr) | Terapeutska sredstva za neurodegenerativne bolesti | |
| WO2014178931A8 (en) | Sobetirome in the treatment of myelination diseases | |
| MX2019003805A (es) | Activadores de flujo autofágico y fosfolipasa d y depuración de acumulaciones de proteína que incluyen tau y tratamiento de proteinopatías. | |
| AU2018264384A1 (en) | Solid forms of berberine ursodeoxycholate and compositions and methods thereof | |
| MY189740A (en) | Butylphthalide-telmisartan heterocomplex, preparation method and application thereof | |
| EA201991756A1 (ru) | Бисгетероарильные производные в качестве модуляторов агрегации белков | |
| CY1124115T1 (el) | Η χρηση τριβενζοϊκου γλυκερυλιου που περιεχει συνθεση σε νευροεκφυλιστικες διαταραχες | |
| EP3452828A4 (en) | BIOMARKERS OF SYNAPTIC PROTEINS AND DIFFERENTIAL DIAGNOSIS OF ALZHEIMER'S DISEASE AND OTHER NEURODEGENERATIVE DISORDERS | |
| SG11201705986QA (en) | Antibody molecules and peptide delivery systems for use in alzheimer's disease and related disorders | |
| EA201991374A1 (ru) | Водорастворимое производное эпиаллопрегнанолона и его применение | |
| IL278813A (en) | Gene therapy for alzheimer's disease | |
| EP3639839A4 (en) | PEPTIDE WITH ANTIDEPRESSIVE EFFECT AND THERAPEUTIC EFFECT AGAINST ALZHEIMER'S MORBUS | |
| EP3835424A4 (en) | DIAGNOSTIC MEDICINE AND DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE | |
| WO2010000089A8 (en) | Stat3 and tyk2 as drug targets for neurodegenerative diseases | |
| EP3768836A4 (en) | ANIMAL MODEL OF ALZHEIMER'S DISEASE AND ITS USE | |
| JP2018536697A5 (ja) | ||
| EP3982819A4 (en) | METHODS FOR THE ASSESSMENT AND TREATMENT OF ALZHEIMER'S DISEASE AND THEIR APPLICATIONS | |
| EP3802568A4 (en) | PEPTIDE THERAPEUTIC AGENTS FOR THE TREATMENT OF ALZHEIMER'S DISEASE AND RELATED CONDITIONS | |
| EP3372249C0 (en) | AAV/UPR-PLUS VIRUS, UPR-PLUS FUSION PROTEIN, GENETIC TREATMENT METHOD AND USE THEREOF IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS PARKINSON'S DISEASE AND HUNTINGTON'S DISEASE |